Morningstar analysts do not currently cover PNH, but with our powerful screener, you can find stocks in the same sector,industry, or style and filter on our unbiased ratings and valuation metrics.

See the committee papers for full details of the evidence. Paroxysmal nocturnal haemoglobinuria (PNH) is a rare blood condition caused by an acquired mutation of the PIG‑A gene within bone marrow stem ...

Novartis’ Fabhalta (iptacopan) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat paroxysmal nocturnal haemoglobinuria (PNH) in adults with haemolytic ...

Tesidolumab is under clinical development by Novartis and currently in Phase II for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData, Phase II drugs for Paroxysmal Nocturnal Hemoglobinuria ...

Roche’s PiaSky is the first monthly subcutaneous therapy for PNH approved in the European Union. Credit: Poetra.RH/Shutterstock. The European Commission (EC) has approved Roche’s recycling monoclonal ...

Night Magic: Adventures among Glowworms, Moon Gardens, and Other Marvels of the Dark by Leigh Ann Henion. Algonquin, 2024 ($30) I recently returned from a camping trip with legs covered in bug ...

That gnarly old buck just lays there, chewing his cud and wasting the day. Then, about 20 minutes after nightfall, he rises, stretches, and departs for distant fields. As a result, this buck is ...